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Abstract
Introduction: High-frequency ultrasound offers a potential for objective and quantitative assessment of skin
thickness and skin echogenicity in systemic sclerosis (SSc). Few studies have however assessed the longitudinal
changes of skin involvement using ultrasound. The aim of the study was to investigate changes in skin thickness in
early SSc using high frequency ultrasound during one year of follow-up in comparison to other measurements of
skin fibrosis.
Methods: This retrospective study comprised 75 consecutive patients with disease duration shorter than 3 years, in
whom ultrasound examination of skin thickness was performed at baseline and at the one year follow-up at five
predefined sites.
Results: Repeated ultrasound examination identified significant changes in a majority of patients. In 21 patients, the
total sum of skin thickness (TST) increased, while TST decreased in 37 patients. On a group level there were significant
decreases in skin thickness of the chest (p = 0.024) and in the TST (p = 0.011) during the observation time. Both
baseline and follow-up TST correlated to serum-COMP (rS: 0.41; p = 0.001; rS: 0.49; p < 0.001), modified Rodnan skin
score (mRSS; rS: 0.48; p < 0.001; rS: 0.48; p < 0.001) and hand mobility in scleroderma (HAMIS; rS: 0.30; p = 0.043; rS: 0.64;
p < 0.001). Changes in TST correlated with changes in serum-COMP (rS: 0.30; p = 0.034), changes in mRSS (rS: 0.43;
p < 0.001) and changes in HAMIS (rS: 0.53; p = 0.001) during follow-up.
Conclusions: In early SSc, skin thickness measured by high frequency ultrasound develops in parallel with serum-COMP,
mRSS and the HAMIS test. Ultrasound examination of the skin allows for objective assessment of one facet of the
complex process of skin fibrosis in early SSc.
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Introduction
Systemic sclerosis (SSc, scleroderma) is characterised by
fibrosis, progressive vascular obliteration and the pro-
duction of autoantibodies. The fibrotic process can tar-
get the skin and internal organs and there have been
several attempts to quantify both the severity and the
activity of such process. The established method of skin
assessment is the semi-quantitative scoring (Rodnan skin
score, RSS), introduced by Rodnan in 1979, which is
used world-wide with variations in definitions of the
score grades per anatomical site or number of sites to
score [1]. The activity of the fibrosis may also be
assessed by the measurement of biomarkers in serum,
such as cartilage oligomeric matrix protein (COMP), an
extra-cellular matrix molecule produced by fibroblasts
during development of fibrosis [2]. The consequences of
the fibrosis may be assessed by the hand mobility in
scleroderma (HAMIS) test which was specifically devel-
oped for patients with SSc [3].
High-frequency ultrasound offers a potential for
objective and quantitative assessment of skin thickness
and skin echogenicity in SSc. It has been shown to be a
valid measurement of skin thickening with a high correl-
ation to RSS [4]. Cross sectional studies have shown
excellent inter- and intraobserver variability for dermal
* Correspondence: roger.hesselstrand@med.lu.se
Department of Clinical Sciences, Section of Rheumatology, Lund University,
Lund, Sweden
© 2015 Hesselstrand et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hesselstrand et al. Arthritis Research & Therapy  (2015) 17:329 
DOI 10.1186/s13075-015-0853-5
thickness in particular with intraclass correlation (ICC)
often > 0.8 for interobserver variability and > 0.9 for
intraobserver variability [5–7]. In SSc patients with short
disease duration, high frequency ultrasound can identify
the oedematous phase, which may precede palpable skin
involvement, and may thus be useful to identify patients
with diffuse skin involvement very early in the disease
process [4, 7]. Ultrasound measurements also reflect the
severity of the overall fibrotic skin involvement [4]. In
addition, dermal finger thickness importantly is associ-
ated with nailfold microangiopathy severity assessed by
capillaroscopy [8].
Few studies have assessed the longitudinal changes of
skin involvement using ultrasound. In a longitudinal
pilot study of 16 patients with early SSc and 16 controls,
diffuse cutaneous SSc (dcSSc) patients but not limited
cutaneous SSc (lcSSc) patients had thicker skin and
lower skin echogenicity than controls. Unlike healthy
individuals, these SSc patients displayed large intraindi-
vidual variation over time; during the follow-up, skin
thickness decreased and skin echogenicity increased [6].
In another small study we demonstrated larger in vitro
production of proteoglycans from skin fibroblasts from
patients with significant dynamics in skin echogenicity [9].
The aim of the present study was to study changes in
skin thickness in early SSc using high frequency ultra-
sound during one year of follow-up in comparison to
other measurements of skin fibrosis.
Methods
Subjects
All 75 patients fulfilled the 2013 ACR/EULAR criteria
[10] and 72/75 fulfilled the 1980 ACR criteria for SSc
[11]. Ultrasound examination is performed in all SSc pa-
tients in our department at the first visit. For the pur-
pose of this study, patients with short disease duration
were selected for repeated ultrasound examination at
one-year follow up. This retrospective study comprises
75 patients with disease duration < 3 years at their first
ultrasound examination with one year follow up who
were all investigated by the same co-author (MW), at
the Department of Rheumatology, Skåne University
Hospital, Lund, Sweden. All patients had been examined
according to the mRSS by one of four physicians. The
disease was classified as dcSSc or lcSSc according to the
extent of skin involvement [12]. Skin involvement was
determined by the modified RSS (mRSS) with palpation
of 17 anatomical sites (face, fingers, hands, forearms,
upper arms, chest, abdomen, thighs, legs, and feet) and
scoring on a 0–3 scale, where 0 = normal skin, 1 = slight
thickening, 2 =moderate thickening, and 3 = hidebound
skin sclerosis. The scores for all sites were summed to
give a total score, with a maximum possible score of 51
[13]. The disease onset was defined as the first non-
Raynaud’s manifestation. The mRSS was assessed by one
of four physicians in the scleroderma group trained to
be concordant in the skin scoring technique. Based on a
cohort of 21 patients, the interobserver variability of the
mRSS is limited within this group (ICC: 0.943, 95 % CI
0.868-0.976).
Ethics
The study was approved by the Lund University Ethics
Committee, Lund Sweden. All patients gave their written
permission according to the Declaration of Helsinki.
Ultrasound
Skin thickness and skin echogenicity were measured with
a high frequency ultrasound (US) scanner (Dermascan,
Cortex Technology, Hadsund, Denmark), with 20 MHz
transducer. Two scans were obtained of the tissue: a one
dimensional A mode image with different echoes defining
the interfaces between epidermis, dermis and subcutis,
and a two dimensional B mode image with different col-
ours reflecting the differing echogenicities of the skin. The
echogenicity in the dermal region was represented on an
arbitrary scale (0–255 pixels) where a low value represents
high water content, suggesting oedema. In contrast, a high
value represents dense extra-cellular matrix content, often
seen after the oedema has disappeared. The echogenicity
was calculated by outlining a block of skin in which the
mean echogenicity was estimated for a selected region [6].
All measurements were made by the same observer
(MW) who performed and read the ultrasound examina-
tions, using the same equipment. Five anatomical sites,
selected in order to monitor disease development over
time were analysed – the dorsal aspect of the mid por-
tion of the proximal phalanx of the right second finger
(phalanx), the area (valley) between the metacarpo-
phalangeal joints II and III of the right hand (hand), the
dorsal aspect of the right forearm 3 cm proximal of the
wrist (forearm), the lateral aspect of the right leg 12 cm
proximal of the ankle joint (leg), and the sternum 2 cm
distal from the upper part of the manubrium (chest).
The intraobserver variability of this method has been
assessed [6]. For the individual patient differences in skin
thickness exceeding mean variability two-fold were con-
sidered as significant changes.
HAMIS and COMP
The HAMIS test focuses on the mobility of the fingers
and wrist, and comprises nine items, employing differ-
ently sized grips and different movements. It reflects the
consequences of skin involvement on hand function and
was specifically developed for patients with SSc [3].
Serum-COMP was measured with a commercial sand-
wich enzyme-linked immunosorbent assay (ELISA) using
two monoclonal antibodies directed against separate
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antigenic determinants on the human COMP molecule
(AnaMar, Lund, Sweden). The detection limit was 0.1 U/L
and the intra- and interassay coefficient of variation
was < 5 %.
Study design
All patients were examined by mRSS and by ultrasound
to determine skin thickness and skin echogenicity. Data
on serum-COMP and HAMIS were used if measured
during the same week as the ultrasound examination.
The ultrasound examination was performed at the
patient’s first visit to the department during the time
period of 1 April 1996 to 1 June 2012. Follow-up data
until 1 June 2013 were retrieved. Complete data on
ultrasound and mRSS were available for all patients at
baseline and at one-year follow-up. Due to the retro-
spective design serum-COMP and HAMIS data were
available in 62 and 54 out of 75 patients at baseline and
in 55 and 46 out of 75 patients at follow-up.
Statistical methods
The distribution of several of the analysed variables was
moderately skewed. Non-parametric statistics are used
throughout the manuscript. Differences between groups
were analysed using the related-samples Wilcoxon
Signed Rank test and the Mann–Whitney U test. Asso-
ciations between variables were analysed using the




Clinical features of the patients are displayed in Table 1.
At follow-up median mRSS (IQR) changed from 10
(4.0-19) to 9.0 (4.0-21) points, serum-COMP from 12
(10–17) to 12 (8.6-16) U/Land HAMIS from 6.0 (3.5-14)
to 7.0 (2.0-16).
Change in skin thickness and skin echogenicity during
the first year of observation
The second ultrasound examination was performed at
median (IQR) 14.3 (13.8-15.0) months after the first.
Total sum of skin thickness (TST) at baseline and total
sum of skin echogenicity (TSE) were inversely correlated
(rS: −0.51, p < 0.001). Baseline skin thickness and skin
echogenicity correlated inversely to changes in the same
parameters (rS: −0.36, p < 0.001; rS: −0.48, p < 0.001
respectively), i.e. the higher the baseline skin thickness
the larger was the subsequent reduction in skin thick-
ness. Also, change in TST correlated with change in TSE
(rS: −0.33, p = 0.003). At the group level there were sig-
nificant changes (i.e. a reduction) in skin thickness of
the chest and the TST during the observation time
(Table 2).
Significant changes in skin thickness were noticed in a
majority of the patients at all five sites (Table 3). Patients
who exhibited a significant reduction of skin thickness
on the hand and leg also had a decrease in the mRSS.
This was not true for patients with a significant increase
in the skin thickness on these sites. Patients who exhib-
ited significant increase in skin thickness on the chest
and leg had higher serum-COMP levels at baseline.
Patients with increased skin thickness on the forearm
had worsening of hand function, while the opposite
could be seen in patients with reduction in skin thick-
ness on the forearm. We did not see any correlation be-
tween change in finger skin thickness and the studied
variables.
Change in skin thickness and skin echogenicity in relation
to disease duration
We identified a weak inverse correlation between TST
and disease duration (rS: −0.22, p = 0.056) which was not
statistically significant, although indicating trends to-
wards higher skin thickness when disease duration was
shorter.
Correlation between ultrasound measurements and
mRSS, serum-COMP and HAMIS
Fibrosis is challenging to evaluate. Considering the
simplification that ultrasound mainly measures skin
thickness, mRSS measures severity, serum-COMP re-
flects fibrotic activity and HAMIS the consequences of
fibrosis on hand function, all these measures are closely
related, yet examine different facets of the disease.
Indeed, the ultrasound measurements correlated to
serum-COMP, mRSS, and HAMIS both at baseline and
the one-year follow-up (Table 4). At baseline, TST cor-
related with serum-COMP (rS: 0.41, p = 0.001), mRSS
Table 1 Clinical features at the first ultrasound examination of
the skin of 75 SSc patients
Features Median (IQR)
Age (years) 52.4 (44.8–62.0)
Disease duration (months) 10.9 (7.9–19.1)
mRSS 10.5 (4.0–19)
Serum-COMP (U/L) 12 (10–17) (n = 62)




Immunosuppressive treatment (yes/no)a 39/36 (52/48)
mRSS modified Rodnan skin score, COMP cartilage oligomeric matrix protein,
HAMIS hand mobility in scleroderma test, lcSSc limited cutaneous systemic
sclerosis, dcSSc diffuse cutaneous systemic sclerosis
aCyclophosphamide (n = 16); Azathioprine (n = 10); Methotrexate (n = 7);
Mycophenylate mofetil (n = 12). Six patients received two different treatments
during the first year of follow-up
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(rS: 0.48, p < 0.001) and HAMIS (rS: 0.30, p = 0.043). At
follow-up TST correlated with serum-COMP (rS: 0.49,
p < 0.001), mRSS (rS: 0.48, p < 0.001) and the correlation
to HAMIS increased further (rS: 0.64, p < 0.001). At
baseline, TSE correlated with serum-COMP (rS: −0.28,
p = 0.025), mRSS (rS: −0.40, p = 0.001) but the correlation
to HAMIS was not significant (rS: −0.28, p = 0.066). At
follow-up, the correlation between TSE and serum-
COMP was no longer significant (rS: −0.16, p = 0.23),
whereas there was still a weak correlation to mRSS
(rS: −0.24, p = 0.044) but no significant correlation to
HAMIS (rS: −0.26, p = 0.087).
On average, changes in TST correlated with changes
in serum-COMP (rS: 0.30, p = 0.034), mRSS (rS: 0.43,
p < 0.001) and strongly with changes in HAMIS (rS: 0.53,
p = 0.001) during the same time period, i.e. a reduction in
Table 2 Comparison between skin ultrasound examination at baseline and at the one-year follow-up
Measurement normal valuesa baseline follow-up change p
(95 % CI) median (IQR) median (IQR) median (IQR)
Skin thickness (mm) (mm) (MM)
Phalanx (1.15–2.11) 2.14 (1.92–2.37) 2.05 (1.88–2.33) −0.02 (−0.22 – 0.13) 0.28
Hand (0.98–1.47) 1.51 (1.39–1.71) 1.50 (1.34–1.66) −0.040 (−0.18 – 0.12) 0.14
Forearm (1.05–1.75) 1.61 (1.44–1.76) 1.55 (1.30–1.76) −0.080 (−0.23 – 0.10) 0.052
Leg (1.02–1.64) 1.47 (1.33–1.62) 1.43 (1.29–1.55) −0.040 (−0.16 – 0.06) 0.060
Chest (1.04–1.89) 1.63 (1.50–1.92) 1.58 (1.44–1.79) −0.12 (−0.30 – 0.15) 0.024
TST (5.62–8.59) 8.53 (7.94–9.03) 8.28 (7.47–8.94) −0.22 (−0.79 – 0.30) 0.011
Skin echogenicity (pixels)
Phalanx (15.0–44.0) 25.0 (20.0–30.0) 24.5 (21.0–31.0) 0.0 (−4.0 – 4.0) 0.78
Hand (19.0–47.0) 29.0 (22.5–34.0) 28.0 (22.0–35.0) 0.0 (−5.0 – 6.0) 0.59
Forearm (22.0–51.0) 38.0 (33.0–45.5) 37.5 (31.5–46.0) 1.0 (−7.0 – 7.0) 0.49
Leg (31.0–55.0) 47.0 (42.4–56.0) 47.0 (42.4–56.0) −0.80 (−6.0 – 9.0) 0.94
Chest (30.0–54.0) 48.0 (41.5–53.0) 48.0 (41.5–53.5) 0.50 (−6.0 – 6.5) 0.53
TSE (136.0–240.0) 188 (168–212) 187 (166–213) −2.5 (−23.5 – 30.0) 0.82
IQR interquartile range, TST total sum of skin thickness, TSE total sum of skin echogenicity
anormal values from previous study [6]
Table 3 Comparison between patients with significant increase or decrease in skin thickness measured by ultrasound at different





















Finger Increase, (18) 9.5 0.250 1.0 0.095 11.7 0.497 1.0 0.150 4.0 0.106 1.5 0.374
Decrease, (27) 11.0 −1.0 12.3 −1.0 7.5 −1.0
Hand Increase, (21) 10.0 0.231 0.0 0.016 12.0 0.750 0.0 0.203 5.0 0.417 0.0 0.540
Decrease, (27) 10.0 −3.0 12.0 −1.6 7.5 −1.0
Forearm Increase, (18) 11.0 0.991 1.5 0.051 15.0 0.467 0.0 0.089 7.0 0.484 4.0 <0.001
Decrease, (30) 10.5 −1.0 12.0 −1.0 5.0 −1.0
Leg Increase, (18) 9.5 0.423 2.0 0.007 15.0 0.029 −0.5 0.986 5.0 0.583 3.0 0.180
Decrease, (29) 10.0 −1.0 11.7 −0.5 7.0 0.0
Chest Increase, (19) 11 0.435 0.5 0.287 15.0 0.029 −1.0 0.940 7.0 0.796 0.0 0.444
Decrease, (41) 10 0.0 11.7 0.0 6.0 0.0
Total Increase, (21) 11 0.802 1 0.019 12.7 0.363 0.0 0.217 5.5 0.344 5.0 0.002
Decrease, (37) 10 −2 12.0 −1.6 8.0 −1.5
Increase in hand skin thickness was associated with absence of improved mRSS. Increase in forearm skin thickness was associated with worsening hand function.
Increase in skin thickness on leg and chest was preceded by high levels of the fibrosis biomarker COMP
US ultrasound, mRSS modified Rodnan skin score, COMP cartilage oligomeric matrix protein, HAMIS hand mobility in scleroderma test
Note to reviewer: The numbers describing COMP baseline with Δthickness on leg and chest are by chance identical, this has been controlled
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skin thickness is accompanied by decreasing COMP pro-
duction, reversal of mRSS and improved hand function
(Table 4).
Discussion
The skin involvement in SSc is a complex process com-
prising ischaemia, inflammation and fibrosis and it is dif-
ficult to distinguish between thick, hard or hidebound
skin. High-frequency ultrasound offers a potential for
quantitative assessment of skin thickness and skin echo-
genicity in SSc. In this longitudinal study during one
year of follow-up we identified significant changes in a
majority of patients on an individual level. Skin thickness
decreased and skin echogenicity increased at all of the
five predefined areas investigated. While we noticed a
reduction of skin thickness on the group level, there was
a great individual variation with several patients showing
worsening of skin thickness during the study period.
Both the decreased thickness and increased echogenicity
were expected and in line with results of our previous
smaller study where most patients gradually became
more similar to the control population during follow-up
[6]. This is further exemplified by the inverse correlation
between skin thickness and disease duration, which
strengthens the notion that in SSc, the skin is thick in
early disease whereas the abnormality of the skin in
long-term disease is mostly related to the skin being
hard and hidebound. This may be exemplified by the
correlation between mRSS and TST, which was 0.48 at
baseline in this study with patients with disease duration
of 1.10 years. In a previous study of patients with disease
duration of two years or less the correlation between
mRSS and TST was 0.66 [4]. However, when those
patients were subdivided the correlation was 0.81 for
patients with disease duration less than one year but
only 0.19 for patients with disease duration of one to
two years. Similar, but less pronounced, differences were
seen in the present study where we found a correlation
of 0.63 in patients with disease duration shorter than
one year and 0.40 in patients with disease duration of
one to three years. Our interpretation is again that mRSS
reflect the increased skin thickness mainly in early
disease and that skin thickness and the mRSS can be
disconnected later on, most notably on the fingers and
back of hands. One year of follow-up was enough to
detect significant decrease or increase in ultrasound
examination of skin thickness in a majority of patients
although a majority of our patients were not yet normal-
ised in skin thickness at this time-point. Of interest,
serum-COMP was associated with dynamics of fibrosis
on the leg and chest which might reflect the substantial
biomass of the skin from these sites compared to the fin-
ger and hands. HAMIS, on the contrary, was associated
with change in skin thickness on the forearm which may
indicate novel speculation on the biological correlates on
reduced hand function in SSc. Finally, skin thickness of
the hand and lower leg was associated with change in
mRSS. This finding might remind us that skin changes
in the distal parts of the arms and legs contribute to 30
of the total maximum 51 points in the mRSS.
TST, both at baseline and at follow-up, correlated with
serum-COMP, and TSE correlated with serum-COMP at
baseline, as previously shown [2], indicating that fibrotic
activity and oedema occur simultaneously. However,
TST correlated with HAMIS to a higher degree at
follow-up than at baseline. It appears that HAMIS
specifically measures the consequences of the fibrotic
activity in the hands and in earlier stages of disease the
skin may be softer although thick [14]. A likely synthesis
of the information from ultrasound, serum-COMP and
HAMIS measurements is that initially increased skin
thickness and fibrotic activity may be accompanied by
swollen but soft skin, thus less correlated to HAMIS. In
advanced disease there is less oedema and the increased
skin thickness may be caused by the accumulation of
matrix components leading to fibrosis and impaired
hand mobility. SSc is a heterogeneous disease with
profound interindividual variations in dynamics in
fibrotic development. For the time being we are cautious
to suggest a certain clinically relevant change in ultra-
sound measurements for an individual patient, not at
least since a normalisation of TST or TSE still can be
followed by an impaired function.
Strengths of this study are the use of one single obser-
ver for all ultrasound examinations and a low number
(four) of observers performing mRSS. Limitations of the
study are the retrospective design resulting in incom-
plete data on serum-COMP and HAMIS-measurements
and the small sample size making subgroup analyses
uncertain. Also, although the correlations observed are
Table 4 Correlations between skin ultrasound examination and
serum-COMP, mRSS, and HAMIS
Baseline rS (p)
serum-COMP mRSS HAMIS
TST 0.41 (0.001) 0.48 (<0.001) 0.30 (0.043)
TSE −0.28 (0.025) −0.40 (0.001) −0.28 (0.066)
1-year follow-up rS (p)
serum-COMP mRSS HAMIS
TST 0.49 (<0.001) 0.48 (<0.001) 0.64 (<0.001)
TSE −0.16 (0.23) −0.24 (0.044) −0.26 (0.087)
rS (p)
serum-COMP change mRSS change HAMIS change
Change in TST 0.30 (0.034) 0.43 (<0.001) 0.53 (0.001)
COMP cartilage oligomeric matrix protein, mRSS modified Rodnan skin score,
HAMIS hand mobility in scleroderma test, TST total sum of skin thickness,
TSE total sum of skin echogenicity
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statistically significant and point in the same direction
they are often of weak to moderate strength. Finally, a
majority of the patients received immunosuppressants
including prednisone between the two ultrasound
examinations. It cannot be ruled out that some of the
changes identified in this study on both skin thickness
and other variables studied are partly explained by these
medications.
Conclusions
Fibrosis is a complex process to analyse objectively.
Ultrasound offers a unique perspective to evaluate skin
thickness objectively. In early SSc, skin thickness mea-
sured by high frequency ultrasound develops in parallel
with serum-COMP, mRSS, and the HAMIS test. Ultra-
sound examination of the skin allows for objective
assessment of one facet of the complex process of skin
fibrosis in early SSc.
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